A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline-Taxane Chemotherapy in Early HER-2 Negative Breast Cancer

Overview

Journal Curr Oncol

Publisher MDPI

Date 2025 Jan 24

PMID 39851922

Authors

Danilo Giffoni de Mello Morais Mata

Rossanna C Pezo

Kelvin K W Chan

Ines Menjak

Andrea Eisen

Maureen Trudeau

Affiliations

Soon will be listed here.

Abstract

Background: Anthracycline-taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC).

Methods: Through a retrospective study of stage I-III HER2-negative BC, using administrative databases, we analyzed a total of 10,634 women treated with adjuvant chemotherapy in Ontario, Canada, between 2009 and 2017. We compared TC versus standardized anthracycline-taxane chemotherapies (ACT and FEC-D). We investigated the overall survival (OS), and explored the incidence of CHF, emergency department (ED) visits and febrile neutropenia.

Results: With a median follow-up of 5.5 years, the 5-year analysis showed an increased OS in patients treated with TC, versus those treated with ACT, HR 0.77 (0.63-0.95, = 0.015). Among ER+ BC, there was an increased OS in patients treated with ACT and FEC-D, versus those treated with TC, HR 0.70 (0.52-0.95, = 0.021) and HR 0.71 (0.56-0.91, = 0.007), respectively. There were no substantial differences in CHF, between TC and anthracycline-based treatments. Patients treated with TC and FEC-D had more ED visits, compared to those treated with ACT.

Conclusion: Our study shows that anthracycline-taxane regimens were the most commonly prescribed adjuvant chemotherapy options in HER2-negative BC. Women who received ACT had the lowest OS, likely due to their unfavorable pathology.

References

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, DAscenzo F, Malavasi V . Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013; 112(12):1980-4. DOI: 10.1016/j.amjcard.2013.08.026. View

Peto R, Davies C, Godwin J, Gray R, Pan H, Clarke M . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2011; 379(9814):432-44. PMC: 3273723. DOI: 10.1016/S0140-6736(11)61625-5. View

Jones S, Savin M, Holmes F, OShaughnessy J, Blum J, Vukelja S . Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006; 24(34):5381-7. DOI: 10.1200/JCO.2006.06.5391. View

Kalinsky K, Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D . 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021; 385(25):2336-2347. PMC: 9096864. DOI: 10.1056/NEJMoa2108873. View

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S . Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022; 386(6):556-567. DOI: 10.1056/NEJMoa2112651. View

Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 36(20):2105-2122. DOI: 10.1200/JCO.2018.77.8738. View

Caparica R, Bruzzone M, Poggio F, Ceppi M, de Azambuja E, Lambertini M . Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2018; 174(1):27-37. DOI: 10.1007/s10549-018-5055-9. View

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P . 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017; 377(19):1836-1846. PMC: 5734609. DOI: 10.1056/NEJMoa1701830. View

10.

Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J . Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015). Breast. 2018; 39:131-138. DOI: 10.1016/j.breast.2018.03.002. View

11.

Fountzilas G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki A . Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer. 2014; 14:515. PMC: 4223601. DOI: 10.1186/1471-2407-14-515. View

12.

Yersal O, Barutca S . Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014; 5(3):412-24. PMC: 4127612. DOI: 10.5306/wjco.v5.i3.412. View

13.

Batra A, Hannouf M, Alsafar N, Lupichuk S . Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study. Breast. 2020; 54:1-7. PMC: 7475113. DOI: 10.1016/j.breast.2020.08.002. View

14.

Masuda N, Lee S, Ohtani S, Im Y, Lee E, Yokota I . Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017; 376(22):2147-2159. DOI: 10.1056/NEJMoa1612645. View

15.

Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J . Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020; 382(9):810-821. DOI: 10.1056/NEJMoa1910549. View

16.

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378(9793):771-84. PMC: 3163848. DOI: 10.1016/S0140-6736(11)60993-8. View

17.

Gent D, Rebecca D . The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus. Eur Cardiol. 2023; 18:e16. PMC: 10316349. DOI: 10.15420/ecr.2022.63. View

18.

Alferez D, Simoes B, Howell S, Clarke R . The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells. Curr Stem Cell Rep. 2018; 4(1):81-94. PMC: 5866269. DOI: 10.1007/s40778-018-0114-z. View

19.

John P, Osani M, Kodali A, Buchsbaum R, Bannuru R, Erban J . Comparative Effectiveness of Adjuvant Chemotherapy in Early-Stage Breast Cancer: A Network Meta-analysis. Clin Breast Cancer. 2020; 21(1):e22-e37. DOI: 10.1016/j.clbc.2020.07.005. View

20.

Huo X, Li J, Zhao F, Ren D, Ahmad R, Yuan X . The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021; 21(1):78. PMC: 7816481. DOI: 10.1186/s12885-021-07791-y. View